^
Association details:
| Biomarker: | EGFR expression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | MRG003 (Microtubule inhibitor, EGFR-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
905P FIH phase I dose escalation and dose expansion study of anti-EGFR ADC MRG003 in patients with advanced solid tumors
Published date:
09/01/2021
Excerpt:
...a total of 39 pts with CRC (12), SCCHN (13), and NPC (14) were enrolled in Ph Ib with pre-screening of EGFR by IHC….Among 18 of 22 pts who had tumor evaluation in Ph Ia, the ORR was 6% and DCR was 33%; Among 27 of 39 pts evaluable for efficacy in Ph Ib, the BOR was 11 PR (8 confirmed) and 9 SD, the ORR was 30% and DCR was 63%. The ORR was 40% and DCR was 80% for SCCHN, and the ORR was 44% and DCR was 78% for NPC.
DOI:
https://doi.org/10.1016/j.annonc.2021.08.1315
